This Is MS Multiple Sclerosis Knowledge & Support Community

A study by researchers at the Karolinska Institute (Karolinska Institutet), University of Gothenburg and Umea University (Umeå universitet) has found that rituximab provides better clinical outcomes than fingolimod (Gilenya), in people with MS that have ceased natalizumab (Tysabri) treatment due to becoming JCV+.

Full summary available: http://www.mstranslate.com.au/rituximab ... dividuals/